Innovent Biologics vs Eli Lilly vs Novo Nordisk and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Innovent Biologics 0.582, Eli Lilly 22.974, Novo Nordisk 12.087, Pfizer 15.034.
* Innovent Biologics reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Innovent Biologics, Eli Lilly, Novo Nordisk, Pfizer.| Metric | Innovent Biologics | Eli Lilly | Novo Nordisk | Pfizer |
|---|---|---|---|---|
| Market Cap | $21.66B | $1.03T | $165.67B | $156.74B |
| Revenue | $1.16B | $22.97B | $12.09B | $15.03B |
| Cost of Revenue | $175.00M | $3.27B | $2.63B | $4.09B |
| Gross Profit | $989.00M | $19.71B | $9.45B | $10.94B |
| Operating Income | $258.00M | $12.46B | $4.17B | $4.71B |
| Net Income | $169.00M | $7.09B | $3.23B | $-246.00M |
| R&D Expense | $227.00M | $3.82B | $2.74B | $2.81B |
| Earnings Per Share | $0.09 | $7.94 | $0.73 | -$0.04 |
| Gross Margin | 85.0% | 85.8% | 78.2% | 72.8% |
| Operating Margin | 22.1% | 54.2% | 34.5% | 31.3% |
| Net Profit Margin | 14.5% | 30.9% | 26.7% | -1.6% |
| Free Cash Flow | $489.00M | $7.76B | $6.53B | $302.00M |
| Cumulative Free Cash Flow | $229.00M | $109.66B | $107.39B | $356.70B |
| Operating Cash Flow | $513.00M | $10.69B | $8.50B | $835.00M |
| Cash & Equivalents | $2.38B | $8.89B | $6.85B | $976.00M |